- Home
- AOMR vs KROS Comparison
AOMR vs KROS Comparison
Compare AOMR & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AOMR | KROS |
|---|---|---|
| Founded | 2018 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 191.5M | 222.7M |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | AOMR | KROS |
|---|---|---|
| Price | $6.17 | $9.50 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 7 |
| Target Price | $9.15 | ★ $19.83 |
| AVG Volume (30 Days) | 115.4K | ★ 142.0K |
| Earning Date | 11-03-2026 | 11-05-2026 |
| Dividend Yield | ★ 20.64% | N/A |
| EPS Growth | 53.85 | ★ 146.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $243,864,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.94 | $8.98 |
| 52 Week High | $9.30 | $22.55 |
Technical Indicators
Market Signals| Indicator | AOMR | KROS |
|---|---|---|
| Relative Strength Index (RSI) | 33.70 | 31.97 |
| Support Level | N/A | N/A |
| Resistance Level | $9.24 | $11.86 |
| Average True Range (ATR) | 0.29 | 0.62 |
| MACD | -0.07 | -0.21 |
| Stochastic Oscillator | 15.91 | 16.03 |
Price Performance
Historical ComparisonAbout AOMR Angel Oak Mortgage REIT Inc.
Angel Oak Mortgage REIT Inc is a real estate finance company focused on acquiring and investing in first and second lien non-QM loans and other mortgage-related assets in the U.S. mortgage market. Its objective is to generate attractive risk-adjusted returns for its stockholders, through cash distributions and capital appreciation, across interest rate and credit cycles. The company operates in a single operating segment, which is to acquire, invest in, and finance mortgage-related assets.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.